Yoshida Kosuke, Yokoi Akira, Suzuki Hironori, Tamauchi Satoshi, Kitagawa Masami, Inami Eri, Nakayama Jun, Mori Yutaro, Okamoto Koji, Suzuki Yutaka, Yoshida Hiroshi, Kato Tomoyasu, Kajiyama Hiroaki, Yamamoto Yusuke
Department of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Institute for Advanced Research, Nagoya University, Nagoya, Japan.
Cancer Sci. 2025 May;116(5):1339-1351. doi: 10.1111/cas.70022. Epub 2025 Feb 13.
Squamous cell carcinoma arising from mature teratoma (SCC-MT) is a rare ovarian malignancy. The detailed molecular pathology of SCC-MT is not well understood. Moreover, the prognosis of the patients remains poor because no standard treatment has been established. In this study, we performed single-nucleus RNA sequencing and spatial transcriptomics using clinical SCC-MT samples to identify novel therapeutic candidates. snRNA-seq revealed three epithelial cell clusters, of which one was significantly associated with epidermis and keratinocyte development. Moreover, spatial transcriptomics revealed that the epithelial-mesenchymal transition was significantly inhibited, and the MYC and E2F targets were significantly activated in cancer spots on specimen sections. We focused on KLF5, which was one of the upregulated genes in cancer cells, and performed a functional analysis using NOSCC-1, a cell line derived from an SCC-MT. KLF5 downregulation significantly decreased cell proliferation and increased apoptosis. Furthermore, we previously identified miR-145-5p as a downregulated miRNA in SCC-MT. We demonstrated that miR-145-5p overexpression attenuated cell proliferation and decreased KLF5 expression. In conclusion, through multi-omics analyses, we identified unique gene expression profiles of SCC-MT and determined a role for KLF5 in SCC-MT development. Therefore, KLF5-related factors may be novel therapeutic targets, and further studies are needed to improve the diagnosis and treatment of SCC-MT.
成熟畸胎瘤来源的鳞状细胞癌(SCC-MT)是一种罕见的卵巢恶性肿瘤。SCC-MT的详细分子病理学尚不清楚。此外,由于尚未确立标准治疗方法,患者的预后仍然很差。在本研究中,我们使用临床SCC-MT样本进行了单核RNA测序和空间转录组学分析,以确定新的治疗候选物。snRNA-seq揭示了三个上皮细胞簇,其中一个与表皮和角质形成细胞发育显著相关。此外,空间转录组学显示上皮-间质转化受到显著抑制,并且在标本切片的癌灶中MYC和E2F靶点被显著激活。我们聚焦于KLF5,它是癌细胞中上调的基因之一,并使用源自SCC-MT的细胞系NOSCC-1进行了功能分析。KLF5的下调显著降低了细胞增殖并增加了细胞凋亡。此外,我们之前鉴定出miR-145-5p是SCC-MT中下调的miRNA。我们证明miR-145-5p的过表达减弱了细胞增殖并降低了KLF5的表达。总之,通过多组学分析,我们确定了SCC-MT独特的基因表达谱,并确定了KLF5在SCC-MT发生中的作用。因此,KLF5相关因子可能是新的治疗靶点,需要进一步研究以改善SCC-MT的诊断和治疗。